<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040453</url>
  </required_header>
  <id_info>
    <org_study_id>EPN 2016/2212-31/2</org_study_id>
    <nct_id>NCT03040453</nct_id>
  </id_info>
  <brief_title>Immunological Response After Ablative Therapy in the Liver</brief_title>
  <acronym>IRAL</acronym>
  <official_title>Comparison of Immunological Response After Microwave Ablation and Irreversible Electroporation of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local ablative treatment of Hepatocellular Carcinoma is performed primary on patients not
      eligible for liver transplant or liver resection. At our Hospital two different methods are
      used: Microwave ablation, where the tumor cells are heated up and killed, and Irreversible
      electroporation, where the tumor cells are exposed to an electrical field and nano-pores are
      formed in the cell membranes and the cells go into apoptosis (programed cell death).

      Previous studies have shown effects on the immune system after ablative therapies.

      The purpose of this study is to compare the immunological response after the wo different
      methods of killing the tumor cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological response</measure>
    <time_frame>Change from baseline (morning of the procedure) measured at post operative day 1,7, 28 and 90</time_frame>
    <description>Change in immunological response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with complete radiological response at follow up 3, 6, 9 and 12 months.</measure>
    <time_frame>Follow-up every three months for one year with CT scan.</time_frame>
    <description>Compare the effect of the two different ablative methods</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Immune Response</condition>
  <arm_group>
    <arm_group_label>Microwave ablation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 patients will be treated with microwave ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irreversible electroporation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 patients will be treated with irreversible electroporation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microwave ablation</intervention_name>
    <arm_group_label>Microwave ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Irreversible electroporation</intervention_name>
    <arm_group_label>Irreversible electroporation</arm_group_label>
    <other_name>Nano Knife, Angiodynamics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatocellular carcinoma, maximum 3 lesions, maximum 30 mm in any cross section
             diameter

          -  Physically fit to undergo general anaesthesia

          -  Fully understand swedish instructions regarding the study

        Exclusion Criteria:

          -  Atrial fibrillation (for irreversible electroporation)

          -  Pacemaker (for irreversible electroporation)

          -  &gt;3 lesions

          -  &gt; 30 mm in any cross section diameter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Freedman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Instituet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Stillstrom, MD</last_name>
    <email>david.stillstrom@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Surgery and Urology, Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Stillstrom, MD</last_name>
      <email>david.stillstrom@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>David Stillstr√∂m</investigator_full_name>
    <investigator_title>Consultant Surgeon</investigator_title>
  </responsible_party>
  <keyword>Irreversible electroporation</keyword>
  <keyword>Microwave ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

